For this issue of Manager of the Month we profile Geneva-based GP Gyrus Capital, a sector-focused European mid-market firm specialising in Healthcare and Services investments, particularly corporate carve-outs and founder transitions.
GP Overview –
Status: Emerging | Geography: Europe / North America | Market Cap: Lower Mid Cap | Sectors: Healthcare & Services
Gyrus Capital (“Gyrus”) is a Geneva, Switzerland-based private equity firm founded in October 2018 by Guy Semmens and Dr Robert Watson. Semmens, the former Managing Partner of Argos Soditic with over 25 years of PE experience, brought the institutional fund-management discipline; Watson, a former Managing Director at Altaris Capital Partners in New York with prior stints at HgCapital, Ares Life Sciences and Sofinnova Partners (and a published neuroscientist before turning to investing) brought the deep healthcare sector specialism. Together they built a firm with a deliberately narrow remit: transformational investments in two sectors only, executed primarily through complex deal structures.
Eight years on, Gyrus has raised approximately €1.4 billion of capital across its principal funds and co-investment vehicles, built a team of 13 investment professionals, and executed a series of marquee carve-outs from corporate parents including DuPont (dss+), LivaNova (Corcym), and PwC Italy (Intellera). The firm makes two to three investments per year and, to date, has reported that 100% of its investments have been sourced off-market.
Strategy
Gyrus operates a single, focused investment strategy executed through successive principal funds and co-investment vehicles. The firm targets businesses with enterprise values typically in the €50 million to €500 million range, though the official mandate extends up to €1 billion in enterprise value, across Western Europe and North America. Deal types include majority and significant minority buyouts (with control or governance rights) and selective growth capital investments.
Within its two sector verticals, Gyrus is precise about its sub-sector targets. In Healthcare, the firm covers pharmaceuticals, medtech, life sciences and diagnostics, healthcare services and technologies, and animal health. In Services, the focus is on businesses tied to structural macro themes: digital transformation, automation, energy transition, resource efficiency, and the circular economy. The two-sector framing belies a sharper underlying thesis, that these are markets where structural growth drivers operate independently of economic cycles, and where Gyrus believes it can leverage operating partner expertise to drive accelerated value creation.
Underpinning everything is the “Four Foundations” investment framework:
(1) Fundamental Need — addressing major structural needs of society driven by demographics, technology, or the environment;
(2) Resilience — backing businesses with durable market fundamentals not reliant on discretionary spending or regulatory loopholes;
(3) Efficiency — enabling new models, technologies and services that allow society to do more with less; and
(4) Transition — transforming the strategic profile of businesses to accelerate growth and achieve outsized returns. Every investment must, in Gyrus’s view, satisfy all four.
Deal-type focus is a defining feature. Roughly half of the portfolio to date consists of corporate carve-outs from large listed or private parents: dss+ from DuPont, Corcym from Nasdaq-listed LivaNova, Intellera from PwC Italy, LRE Medical from KPS-backed AIS Global. The balance comprises founder- and family-led businesses in succession transitions: Essential Pharma, Neo Medical, Consulcesi Group, ACBC, Katalist. Gyrus markets itself to corporate sellers and founders alike as a partner capable of navigating the operational, legal and IT complexity of separation and standalone-build.
Value creation, post-close, rests heavily on the Entrepreneur Operator Network (EON), a curated bench of senior industry executives engaged across sourcing, diligence, board chairmanships, and co-investment. The network functions as a quasi-operating-partner programme without the standing headcount, allowing the firm to maintain its lean 13-person structure.
Team and Operational Infrastructure
Gyrus today employs 13 investment professionals based at its Quai du Mont-Blanc office in Geneva. The firm’s deliberate scale is part of its self-presentation “a lean and flexible organisation structure that allows us to act rapidly and allocate resources efficiently,” per the firm’s own materials.
The partnership is led by the two co-founders: Guy Semmens (Managing Partner & Co-Founder), formerly Managing Partner at Argos Soditic with overall responsibility for the firm’s management, fundraising, IR and back-office, and before that a member of Clifford Chance’s MBO practice; and Dr Robert Watson (Managing Partner & Co-Founder), formerly Managing Director at Altaris Capital Partners (NY), with prior experience at HgCapital, Ares Life Sciences and Sofinnova Partners — and a published neuroscientist into neurodegenerative diseases before transitioning into investing.
Below the co-founders sit five additional partners: Mirco Dilda, Alyson Greenwood, Cédric Perlet, Hannah Tobin, and Christian Wipf. Three Principals, Xaviera Arneodo, Raffaele Magliocca and Mattias Terribilini, round out the senior investment ranks, supported by a Senior Associate and two Associates. The team composition reflects the dual-sector model: a mix of healthcare and broader services PE backgrounds, with prior experience at firms across the European and North American mid-market.
The structural feature that genuinely differentiates Gyrus’s value creation model is the Entrepreneur Operator Network (EON). Rather than retaining a large in-house operating team, Gyrus maintains an engaged network of senior executives across six sub-domains:
- Pharma — includes Lee Morley (Chairman of Essential Pharma), Nikesh Engineer (former CEO of Essential Pharma), Patrick Vink (30+ years in biotech and pharma), and Richard Davies (Deputy Chairman of Alvotech, Chairman of Immodulon).
- Medtech — includes Davide Bianchi (Chairman of Corcym), Christian Mazzi (CEO of Corcym), Vincent Lefauconnier (Founder & CEO of Neo Medical), and Charles Spicer (multiple medtech chairmanships).
- Services — includes Davide Vassallo (CEO of dss+), Andrea Gabardo (Executive President at Engineering Group), Nazir Esmail (Global CIO of SoftwareOne), and Gio Giacobbe (CEO of ACBC).
- Diagnostics & Life Sciences — Klaus Lun (CEO of LRE Medical) and Henrik Schimmel (Chairman of LRE Medical).
- Digital Health and Other — includes Gabriel Eichler (Managing Director at Oak Health Partners) and Lindsay Dibden (former founding Partner and Head of Healthcare at HgCapital).
The EON model is more than a passive advisory roster. Members actively engage in deal sourcing, diligence, co-investment alongside the funds, board positions at portfolio companies, and thematic research.
Portfolio and Performance
Gyrus’s portfolio reflects the firm’s stated investment pace of two to three new deals per year since inception. The current active portfolio comprises seven core companies, roughly evenly split between Healthcare and Services. Each investment tends to carry a specific structural narrative: a carve-out turned into a standalone business, or a founder transition coupled with international expansion.
Select investments include:
- Corcym — The 2021 carve-out of LivaNova’s heart valve business (Nasdaq-listed parent), creating a fully independent MedTech company focused exclusively on surgical structural heart solutions. Operates in over 100 countries with c.850 employees and 50+ years of product heritage.
- Essential Pharma — A UK speciality pharma platform supplying clinically differentiated niche medicines. Under Gyrus’s ownership, the company has been repositioned from a UK-focused generics family business into a global rare disease innovator.
- LRE Medical — A German-headquartered manufacturer of complex devices and analytical instruments for the life sciences industry, acquired in August/September 2023 from KPS-backed AIS Global. LRE operates two German sites with 250+ employees and is positioned in the structurally growing point-of-care diagnostics space.
- Neo Medical — A Swiss medical technology company specialising in spine surgery, in which Gyrus led a strategic equity investment of up to $68m (CHF 58m) in September 2024. The financing supports US expansion, new product deployment, and development of Neo’s AI-driven augmented reality intraoperative platform, ADVISE.
- Consulcesi Group — An Italian provider of Continuous Medical Education (CME), digital marketing, data analytics and legal services to healthcare professionals, acquired July 2022 alongside the founders. The thesis centres on building a pan-European digital healthcare platform; the deal was structured as a 40% stake with founder Massimo Tortorella and management remaining involved.
- Katalist — A digital software implementation platform for pharmacy and food chains, sitting within the Services portfolio.
- ACBC (Anything Can Be Changed) — Acquired April 2025; a Milan-based Circular Science company and certified B Corp providing advanced R&D, product innovation, and sustainable circular solutions to the fashion and lifestyle industries. ACBC completed the acquisition of Maxima Design in 2025 and represents the firm’s most recent platform investment, anchoring its Services thesis on circular economy and sustainability.
On the exits side, Gyrus has executed two notable monetisations to date. Intellera Consulting, a Milan-based management consultancy originally carved out from PwC Italy in 2021, was sold to Accenture in April 2024. dss+ (formerly DuPont Sustainable Solutions, carved out from DuPont in 2019) saw Inflexion acquire a majority stake from Gyrus, with the firm continuing to hold a meaningful position. StepStone Group has also provided a liquidity solution to Gyrus’s LPs through a multi-asset secondary transaction involving dss+ and Essential Pharma.
Fundraising
Gyrus’s capital base has been built progressively across two principal funds, an open-ended co-investment vehicle, and a single-asset continuation fund. Gyrus Capital Fund I (2020 vintage) closed in 2021 at €215 million. Gyrus Capital Fund II (2023 vintage) reached final close in late 2023 / early 2024 at €310 million across the principal fund and a paired open-ended co-investment vehicle, allowing larger cheque sizes than Fund I. As a result, Gyrus may be expected to be back to market in late 2026. Gyrus is currently represented by Evercore.
Most significantly, in April 2025 Gyrus held a final close on a €700 million single-asset continuation vehicle for Essential Pharma, initially formed in December 2024, with a final close that landed slightly above its €700m hard cap after over €100m of incremental commitments came in during Q1 2025. The continuation vehicle was led by AlpInvest with significant participation from StepStone Group and meaningful reinvestment from Gyrus and management. Combined with the parallel €300m strategic financing facility from Sixth Street, it represents one of the larger European single-asset continuation transactions of 2024–25.
If you have a manager you think should be featured for “Manager of the Month”, or you are a GP and would like to be featured, reach out to contact@lpgateway.com with your suggestion.
